Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
P
P
Bunnag
G
G
Puavilai
S
S
Chanprasertyotin
S
S
Chandraprasert
S
S
Suwanwalaikorn
A
A
Suthijumroon
Y
Y
Benjasuratwong
A
A
Boonyavarakul
W
W
Nitiyanant
S
S
Sriussadaporn
C
C
Deerochanawong
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D002839:Chromans / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013785:Thailand; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors; D000077288:Troglitazone
D001786:Blood Glucose; D002096:C-Peptide; D002839:Chromans; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone